Medical Developments International (MVP) H2 2025 earnings summary

Executive summary

• Achieved a step change in financial performance for FY25, with group revenue up 18% year-over-year to $39.1m, significant improvements in margins, earnings, and cash flow, and a stable balance sheet to support future growth.

• Delivered volume growth in both pain management (Penthrox) and respiratory segments, meeting all strategic priorities set for the year.

• Transitioned Penthrox distribution in France and Switzerland to experienced partners, and secured HPRA approval for pediatric use in Europe, expanding the addressable market.

• Margin improvements and cost reductions of approximately $4m each, driving a significant turnaround in EBIT and cashflow.

• Set the foundation for sustainable growth, focusing on accelerating volume growth and embedding Penthrox as a standard of care in FY26 and beyond.

Financial highlights

• Group revenue increased by 18% year-over-year to $39.1m; pain management revenue up 23% to $26.2m, respiratory up 9% to $12.9m.

• Underlying EBIT improved by $11.6m, reaching breakeven; reported EBIT up AUD 33 million.

• Net profit after tax reached $0.1m, an improvement of $41m, marking the first full-year net profit in several periods.

• Free cash flow improved by almost $12.9m; cash at period end was $17.8m.

• Gross margin and operating margin improved due to pricing and efficiency gains.

Outlook and guidance

• FY26 will see increased investment in growth initiatives, particularly to drive behavioral change and embed Penthrox as standard of care.

• Expectation of softer underlying EBIT in FY26 due to upfront investment and distribution changes, but stronger long-term financial performance anticipated.

• Launch of pediatric label in Europe and further expansion in the US respiratory market are key priorities.

• Anticipate material increase in Penthrox use in UK and European ambulances in FY27 following pediatric approval.

• Modest cost increase in FY26, mainly in medical and commercial investment, estimated at around AUD 2 million.